MDT stock forecast, quote, news & analysis

Key Takeaways

• Medtronic shares traded near $88.64 as of late September 2026, a decline of roughly 2.8% over the trailing 30 days, keeping the stock within a relatively narrow range.
• The modest pullback reflects ongoing overhang from the MiniMed separation and persistent tariff and currency pressures rather than any deterioration in underlying operating performance.
• Fiscal 2027 first-quarter results delivered revenue of about $9.76 billion and strong growth in Cardiac Ablation Solutions, prompting Medtronic to raise its full-year organic revenue outlook.
• Medtronic offers a dividend yield near 3.2% and has raised its payout for 49 consecutive years, reinforcing its defensive profile.
• Analyst price targets were lifted following the latest quarterly report, though the shares remain below their 2026 highs.

Current Market Snapshot

Medtronic shares have traded in a comparatively subdued range in recent weeks. After closing near $91 in late August 2026, the stock drifted to roughly $88.64, a decline of about 2.8% over the trailing 30 days. This places the move firmly below the threshold that would signal a sharp repricing, underscoring a market that is weighing solid fundamentals against structural uncertainties tied to the company's corporate reorganization.

Broader sentiment in the medical technology sector has remained mixed, with investors balancing resilient procedure volumes against tariff exposure, foreign-exchange headwinds, and China volume-based procurement dynamics. Within that context, Medtronic's defensive characteristics, including its established dividend, have helped limit downside volatility.

Medtronic (MDT) Business Overview and Competitive Position

Medtronic plc is one of the world's largest medical device and healthcare technology companies, with headquarters in Dublin, Ireland, and an operational presence centered in the United States. The company operates across three primary reportable segments—Cardiovascular, Neuroscience, and Medical Surgical—while its diabetes business was established as a standalone public company, MiniMed Group (MMED), through an IPO earlier in 2026.

Medtronic's portfolio spans cardiac rhythm management, structural heart, coronary and peripheral vascular devices, spinal and cranial technologies, neuromodulation, surgical innovations, and acute care monitoring. Competitive strengths include deep clinical franchises, broad geographic reach, and a diversified product line that reduces reliance on any single therapy area. Investors follow the stock closely for its recurring-revenue characteristics, innovation pipeline in areas such as pulsed field ablation and robotic-assisted surgery, and a dividend track record spanning nearly five decades.

Recent Developments Driving MDT

The most significant catalyst in recent weeks has been the progression of the MiniMed separation. On September 14, 2026, Medtronic launched an exchange offer allowing shareholders to swap Medtronic ordinary shares for MiniMed common stock at a 7% discount, a step designed to complete the split-off of its former diabetes business. The move is expected to sharpen Medtronic's focus on its cardiovascular, neuroscience, and surgical portfolios, though it has also introduced near-term complexity into how the market values the shares.

Fundamental results have remained strong. Medtronic reported fiscal 2027 first-quarter revenue of approximately $9.76 billion, up 13.7% year over year, with non-GAAP diluted EPS rising to $1.14. Cardiac Ablation Solutions grew about 88%, while Cardiovascular revenue increased 18.9% on an organic basis. Management raised its full-year organic revenue growth guidance to a range of 7.25% to 7.75% and lifted the lower end of its non-GAAP EPS outlook to $5.94.

Analyst sentiment turned more constructive after the report. Stifel raised its price target to $95 from $80, and Wells Fargo increased its target to $104 from $102 while maintaining an Overweight rating. Medtronic has also continued a targeted acquisition strategy, including its CathWorks transaction tied to an AI-powered coronary diagnostic platform and earlier purchases of Scientia Vascular and SPR Therapeutics, as it builds out high-growth franchises while competing with peers such as Intuitive Surgical (ISRG) and Stryker (SYK).

Trending AI Robots

For traders seeking a data-driven perspective on stocks like Medtronic, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term signal generation to longer-horizon trend analysis. The page is designed to help investors quickly identify strategies that are currently gaining traction across the market. Visitors can browse the selection to see which automated approaches align with their own research process.

2026 Outlook and What Investors Should Watch

Looking ahead, several factors are likely to shape Medtronic's share performance. The completion of the MiniMed separation remains a key near-term event, as the final exchange ratio and post-separation capital allocation will clarify the company's go-forward structure. Investors will also monitor whether the rapid expansion in Cardiac Ablation Solutions can be sustained as the pulsed field ablation market matures and competition intensifies.

Macroeconomic considerations include the impact of tariffs on gross margins, foreign-currency translation effects given Medtronic's international footprint, and demand trends in China. On the innovation front, the ramp of the Hugo robotic-assisted surgery platform and continued tuck-in acquisitions represent potential growth drivers, while pricing pressure in areas such as neuroscience and structural heart remains a watch item. As the company advances toward its fiscal 2027 targets, guidance updates and commentary on procedure volumes will be closely followed signals for the stock's trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations